Navi Mumbai, India

Shrikant Prabhakar Keshav

This inventor holds 1 USPTO granted patent. Top assignee: Glenmark Pharmaceuticals Limited. Active years: 2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shrikant Prabhakar Keshav. Retrieved from https://idiyas.com/inventor/shrikant-prabhakar-keshav

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2017

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Journey of Shrikant Prabhakar Keshav

Introduction

Shrikant Prabhakar Keshav, an innovative inventor based in Navi Mumbai, India, has made significant contributions to the pharmaceutical industry. With a focus on developing processes for drug preparation, he has exemplified the essence of research and development in his field.

Latest Patents

Shrikant holds a noteworthy patent for the "Process for the preparation of rivaroxaban," a crucial anticoagulant medication. This patent details the innovative methods for preparing and purifying rivaroxaban, showcasing his expertise in pharmaceutical processes.

Career Highlights

Currently, Shrikant is associated with Glenmark Pharmaceuticals Limited, where he leverages his inventiveness to advance the company’s portfolio in the pharmaceutical sector. His work not only highlights his skills as a chemist but also contributes to the improvement of healthcare solutions.

Collaborations

Throughout his career, Shrikant has collaborated with notable colleagues such as Sanjay Shashikant Bhise and Hemant Harishchandra Kamble. These collaborations have fostered an environment of creativity and innovation, further enhancing the research outcomes at Glenmark Pharmaceuticals.

Conclusion

Shrikant Prabhakar Keshav's commitment to innovation, exemplified through his patent and collaborative efforts, reflects his significant role in the evolving landscape of pharmaceuticals. As he continues to push the boundaries of what is possible in drug formulation, his work remains a valuable asset to both his company and the industry at large.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…